Purple Biotech
PPBT
12 hedge funds and large institutions have $3.72M invested in Purple Biotech in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 6 closing their positions.
55% more capital invested
Capital invested by funds: $2.4M → $3.72M (+$1.32M)
31% more call options, than puts
Call options by funds: $1.98M | Put options by funds: $1.5M
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
20% less funds holding
Funds holding: 15 → 12 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.41M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$146K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$127K |
| 4 |
CCM
Condor Capital Management
Martinsville,
New Jersey
|
+$96.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$905K |
| 2 |
Morgan Stanley
New York
|
-$596K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$168K |
| 4 |
VF
Virtu Financial
New York
|
-$89K |
| 5 |
O
OrbiMed
New York
|
-$62.5K |
PPBT Hedge Fund Activity: Q2 2021 in Review
12 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q2 2021, worth a combined $3.72M — up 55% from $2.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PPBT and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.41M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $905K sold.
- 12 institutional investors held Purple Biotech (PPBT) as of Q2 2021, down from 15 in Q1 2021.
- Funds reported $3.72M of Purple Biotech stock for Q2 2021, up 55% quarter-over-quarter.
- 3 funds opened new Purple Biotech positions in Q2 2021 and 6 closed out, a net change of -3 holders.
- The largest Purple Biotech buyer in Q2 2021 was Point72 Asset Management, an estimated $2.41M added.
- The largest Purple Biotech seller in Q2 2021 was Renaissance Technologies, an estimated $905K sold.
Based on aggregated 13F filings for Q2 2021.